Views and opinions expressed in this presentation are those of the presenter alone, and do not necessarily reflect the views and opinions of Janssen-Cilag Pty Ltd (Janssen) or any employee thereof. This information is not medical advice and no decision relating to the management of any patient should be made with reliance on the information contained in this presentation. It is your responsibility to prescribe appropriate treatments in accordance with your clinical judgment and by reference to the appropriate Australian Product Information or other information supplied with the relevant product, including in relation to any indication, dosage, route of administration. Doc No: CP-02516
Professor W. Wolfgang Fleischhacker
Managing Director Department of Psychiatry, Psychotherapy and Psychosomatics
Professor W. Wolfgang Fleischhacker, MD, is Professor and Managing Director in the Department of Psychiatry, Psychotherapy and Psychosomatics at the Medical University Innsbruck, Austria. He is a certified psychiatrist and psychotherapist.
After receiving his medical degree from Innsbruck University, Professor Fleischhacker trained at the Departments of Psychiatry and Neurology of the Medical Faculty there. In 1987 he was awarded a Fulbright Scholarship and spent 18 months at Hillside Hospital in New York. Professor Fleischhacker is a member of the editorial boards of several peer reviewed journals, coeditor of the schizophrenia section for Current Opinion in Psychiatry, clinical neuropsychopharmacology field editor for International Journal of Neuropsychopharmacology, deputy editor of Schizophrenia Research and managing editor of the Journal Neuropsychiatrie/Psychiatrie und Psychotherapie.
Professor Fleischhacker’s main research interests relate to schizophrenia and psychopharmacology. They have led to participation in World Health Organization and World Psychiatric Association programs focusing on schizophrenia. He is also a member of the scientific committee of the Austrian Agency for Health and Food Safety and has served as a consultant for the European Medicines Agency.
Chairman of the European Group for Research in Schizophrenia, Fellow of the International College of Neuropsychopharmacology; Fellow of the American College of Neuropsychopharmacology, Fellow of the European College of Neuropsychopharmacology. He is also a member of the Schizophrenia International Research Society, Austrian Society of Psychiatry and Psychotherapy, Austrian Schizophrenia Society, Austrian Association of Biological Psychiatry.